Crossmark

Leiomyosarcoma: Does Location of Primary Help to Determine the Best Systemic Therapy Options?

Published Online: 2021-09-15

Published Print: 2021-11

Authors

Novotny, Jan Philipp

George, Suzanne https://orcid.org/0000-0002-1284-8493
Funding

Funding for this research was provided by:

Deutsche Forschungsgemeinschaft (442654483)
License Information

Text and Data Mining valid from 2021-09-15

Version of Record valid from 2021-09-15
More Information

Article History

Accepted: 11 April 2021

First Online: 15 September 2021

Declarations

:

: Jan Philipp Novotny has received compensation from Roche for service as a consultant; has received reimbursement for travel expenses from PharmaMar and Novartis; and owns stock in Onxeo. Suzanne George receives institutional clinical trial funding from Blueprint Medicines, Deciphera Pharmaceuticals, SpringWorks Therapeutics, Merck, Eisai, Bayer, Pfizer, ARIAD, and Daiichi-Sankyo; has received royalties from UpToDate/Wolters Kluwer for authorship of sarcoma-specific content; has served as a consultant for Deciphera Pharmaceuticals, Blueprint Medicines, and Daiichi-Sankyo; has received speaker’s honoraria from Medscape, Research To Practice, and National Comprehensive Cancer Network; has participated on an independent data monitoring committee on behalf of WCG; is Vice Chair of The Alliance for Clinical Trials in Oncology; is Vice President of Alliance Foundation Trials, LLC; owns stock in Abbott Laboratories; previously owned stock in Allergan and AbbVie; and is a scientific advisory board member for KayoThera.

Document is current